Jean-Paul De Backer

Binding of the antagonist []candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells

Frederik Fierens, Patrick Vanderheyden, Jean-Paul De Backer et al. · European Journal of Pharmacology · 1999 · 87 citations

Inflammation, Molecular Pharmacology, Medicine +7

A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists

Georges Vauquelin, Peter Morsing, Frederik Fierens et al. · Biochemical Pharmacology · 2001 · 61 citations

Signal Transduction, Functional Selectivity, Medicine +8

Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum

Jacques De Keyser, Jean-Paul De Backer, Nadine Wilczak et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 1995 · 40 citations

D3 Dopamine Receptors, Human Striatum, Functional Selectivity +9

Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations

Frederik Fierens, Patrick Vanderheyden, Chantal Roggeman et al. · Biochemical Pharmacology · 2002 · 35 citations

Molecular Pharmacology, Membrane Preparations, Molecular Physiology +9

D2 dopamine receptors in the human brain: heterogeneity based on differences in guanine nucleotide effect on agonist binding, and their presence on corticostriatal nerve terminals

Jacques De Keyser, Hilde Walraevens, Jean-Paul De Backer et al. · Brain Research · 1989 · 34 citations

Agonist Binding, Functional Selectivity, Neuroanatomy +12